Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $SRTS
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/31/2025 | $18.00 | Buy | Lake Street |
11/15/2024 | $12.00 → $14.00 | Buy | Maxim Group |
3/3/2022 | $12.00 → $13.00 | Buy | HC Wainwright & Co. |
2/14/2022 | $10.00 → $12.00 | Buy | HC Wainwright & Co. |
12/2/2021 | $9.00 → $10.00 | Buy | HC Wainwright & Co. |
11/5/2021 | $7.00 → $9.00 | Buy | HC Wainwright & Co. |
8/6/2021 | $6.00 → $7.00 | Buy | HC Wainwright & Co. |
Sensus Healthcare to Participate in the 37th Annual ROTH Conference
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be participating in Roth Capital's 37th Annual ROTH Conference, being held March 17-18 in Dana Point, California. Management will be holding one-on-one meetings with registered investors during the conference. Registered attendees who would like to schedule a meeting with Sensus Healthcare management should contact their ROTH representative or Tirth Patel at tpatel@allianceadvisors.com. About Sensus Healthcare Sensus Healthcare, Inc. is a global pioneer in the
Sensus Healthcare Buys Back Shares
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the company has resumed purchasing shares of its common stock in open-market transactions under a $3.0 million share repurchase program approved by its Board of Directors and announced in August 2023. "We are implementing this program now as we view the repurchase of our common stock as a compelling opportunity at current prices," said Joe Sardano, Chairman and CEO of Sensus Healthcare. "We remain confident in our growth prospects and believe that returning capita
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results
Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS of $0.09 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior year Net income
Lake Street initiated coverage on Sensus Healthcare with a new price target
Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00
Maxim Group reiterated coverage on Sensus Healthcare with a new price target
Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target
HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously
CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
Director Petrelli Anthony Benedict was granted 20,000 shares, increasing direct ownership by 43% to 66,466 units (SEC Form 4)
4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
SEC Form 10-K filed by Sensus Healthcare Inc.
10-K - Sensus Healthcare, Inc. (0001494891) (Filer)
Sensus Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Sensus Healthcare Inc.
SCHEDULE 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
Sensus Healthcare Announces Retirement of Director Samuel O'Rear
BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders. Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv
Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions
BOCA RATON, Fla, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective immediately: Vice President and General Counsel Michael J. Sardano has been promoted to President and General CounselSales Manager Christopher Machuzak has been promoted to Vice President of Sales for the West CoastSoutheast Regional Sales Manager Jeffrey Starling has been promoted to Vice President of Sales for the East Coast In addition, the Company announces the retirement of Steve Cohen, Executive Vice Pre
Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems
BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong. This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region. SRT-100 systems utilize S
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results
Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS of $0.09 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior year Net income
Sensus Healthcare to Report 2024 Fourth Quarter and Full Year Financial Results and Hold Business Update Conference Call on Wednesday, February 5, 2025
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the 2024 fourth quarter and full year on Wednesday, February 5, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin
SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)
SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)
SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)